A incidência do acidente vascular encefálico em pacientes infectados pelo SARS- COV-2, COVID-19: uma revisão de literatura: The incidence of brain vascular accident in patients associated with SARS-COV-2, COVID-19 infection: a literature review

Objetivo: O objetivo do trabalho foi analisar a possível relação entre a covid-19 e os acidentes vascular encefálicos (AVE). Métodos: A pesquisa foi realizada nas bases eletrônicas de dados eletrônicos PubMed, Lilacs e SciELO, nas quais foram selecionados artigos originais publicados entre 2020 e 2022. Os critérios de inclusão foram os artigos originais com texto completo disponível e estudos de casos publicados que analisaram a associação entre acidente vascular encefálico com a doença Covid-19. Foram considerados critérios de exclusão os artigos duplicados e de revisão ou aqueles que não se enquadravam ao tema proposto neste estudo. Resultados: Os principais resultados dos artigos analisados demostraram intrínseca relação entre Covid-19 e AVE, uma vez que o AVE isquêmico em pacientes com covid-19 tendem em alguns casos ocorrer por meio da trombose de grandes artérias, em pacientes com envolvimento pulmonar de grau leve a moderado. Além disso, foi constatado que na maioria dos pacientes houveram a presença de marcadores, como PCR, IL-6 e d-dímero e fibrinogênio elevados, presença frequente de anticorpos antifosfolípides, geração de espécies reativas de oxigênio e trombocitopenia. Ademais, foram identificados aumento dos casos em pacientes que apresentavam alguma comorbidade, como hipertensão e diabetes. Conclusão: Portanto, como os mecanismos das complicações do Covid-19 são recentes, se faz necessário a intensificação    de pesquisas nesta área, afim de agir precocemente nas complicações que a Covid-19 pode ocasionar

Prevalência de arritmias em pacientes com Sars-cov-2 tratados com hidroxicloroquina e azitromicina / Prevalence of arrhytmias in patients with Sars-cov-2 treated with hydroxychloroquine and azithromycin

INTRODUÇÃO: Este estudo tem como objetivo realizar uma revisão de narrativa a respeito da correlação entre o prolongamento do intervalo QT e desenvolvimento de Torsade de Pointes (TdP) em pacientes previamente diagnosticados com a COVID-19 e medicados com Hidroxicloroquina e Azitromicina. METODOLOGIA:  Foram realizadas buscas nas bases de dados PubMed/ MedLine utilizando-se os seguintes descritores: ‘’COVID-19”, ‘’hidroxicloroquine’’, “azithromycin”, “QTc interval”, ‘’arrhythmias’’ e ‘’cardiac’’ com ênfase nos resultados de até 1 ano. RESULTADOS: Um total de trinta e três artigos de periódicos internacionais foram selecionados, totalizando uma amostra de 1191 pacientes confirmados com COVID-19 e tratados com Hidroxicloroquina associado com Azitromicina. Estes pacientes que fizeram uso de HCQ em monoterapia desenvolveram menos anormalidades cardíacas e QTc > 500ms em comparação aos tratados com a combinação desses fármacos. DISCUSSÃO: O estudo identificou um prolongamento excessivo do intervalo qtc nos pacientes em uso combinado da medicação, além de algumas arritmias associadas, principalmente FA e TdP. No entanto, é necessária uma investigação mais ampla, com estudos que demonstrem eficácia no combate ao vírus sem o surgimento de efeitos deletérios. CONCLUSÃO: O desenvolvimento de TdP através do uso de Hidroxicloroquina + Azitromicina foi raro. Entretanto, foi significativo o número de pacientes que apresentaram prolongamento do intervalo QT, em particular aqueles que já possuíam alguma comorbidade

Complicações cardiovasculares decorrentes do uso abusivo de esteroides anabolizantes: uma revisão

Este trabalho tem por objetivo examinar e evidenciar as principais complicações cardiovasculares sucedidas do uso abusivo de esteroides anabolizantes. Sendo o presente estudo uma revisão integrativa, realizado a partir da busca dos seguintes Descritores em Ciências da Saúde (DeCS): cardiovascular; anabolic; steroid. Destes, foram escolhidos apenas artigos publicados de 2021 a 2023, até a data de 24/10/2023, sendo selecionados 14 artigos, em que 5 foram excluídos e somente 9 foram examinados para a produção deste estudo. As complicações cardiovasculares associadas ao uso de esteroide anabolizantes são de grande relevância levando em consideração sua morbidade e mortalidade, uma vez que podem possuir desfechos graves como infarto agudo do miocárdio, acidente vascular cerebral isquêmico e eventos trombóticos. A partir do conhecimento destas informações, necessita-se de um apanhado dos principais estudos acerca desta temática para que seja feita a conscientização dos usuários e da população no geral além de auxiliar no diagnóstico diferencial das etiologias para as referidas complicações cardiovasculares.  &nbsp

Hexapoda Yearbook (Arthropoda: Mandibulata: Pancrustacea) Brazil 2020: the first annual production survey of new Brazilian species

This paper provided a list of all new Brazilian Hexapoda species described in 2020. Furthermore, based on the information extracted by this list, we tackled additional questions regarding the taxa, the specialists involved in the species descriptions as well as the journals in which those papers have been published. We recorded a total of 680 new Brazilian species of Hexapoda described in 2020, classified in 245 genera, 112 families and 18 orders. These 680 species were published in a total of 219 articles comprising 423 different authors residing in 27 countries. Only 30% of these authors are women, which demonstrates an inequality regarding sexes. In relation to the number of authors by species, the majority of the new species had two authors and the maximum of authors by species was five. We also found inequalities in the production of described species regarding the regions of Brazil, with Southeast and South leading. The top 10 institutions regarding productions of new species have four in the Southeast, two at South and with one ate North Region being the outlier of this pattern. Out of the total 219 published articles, Zootaxa dominated with 322 described species in 95 articles. The average impact factor was of 1.4 with only seven articles being published in Impact Factors above 3, indicating a hardship on publishing taxonomic articles in high-impact journals.The highlight of this paper is that it is unprecedent, as no annual record of Hexapoda species described was ever made in previous years to Brazil.Fil: Silva Neto, Alberto Moreira. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Lopes Falaschi, Rafaela. Universidade Estadual do Ponta Grossa; BrasilFil: Zacca, Thamara. Universidade Federal Do Rio de Janeiro. Museu Nacional; BrasilFil: Hipólito, Juliana. Universidade Federal da Bahia; BrasilFil: Costa Lima Pequeno, Pedro Aurélio. Universidade Federal de Roraima; BrasilFil: Alves Oliveira, João Rafael. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Oliveira Dos Santos, Roberto. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Heleodoro, Raphael Aquino. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Jacobina, Adaiane Catarina Marcondes. Universidade Federal do Paraná; BrasilFil: Somavilla, Alexandre. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Camargo, Alexssandro. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: de Oliveira Lira, Aline. Universidad Federal Rural Pernambuco; BrasilFil: Sampaio, Aline Amanda. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: da Silva Ferreira, André. Universidad Federal Rural Pernambuco; BrasilFil: Martins, André Luis. Universidade Federal do Paraná; BrasilFil: Figueiredo de Oliveira, Andressa. Universidade Federal do Mato Grosso do Sul; BrasilFil: Gonçalves da Silva Wengrat , Ana Paula. Universidade do Sao Paulo. Escola Superior de Agricultura Luiz de Queiroz; BrasilFil: Batista Rosa, Augusto Henrique. Universidade Estadual de Campinas; BrasilFil: Dias Corrêa, Caio Cezar. Universidade Federal Do Rio de Janeiro. Museu Nacional; BrasilFil: Costa De-Souza, Caroline. Museu Paraense Emilio Goeldi; BrasilFil: Anjos Dos Santos, Danielle. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Norte. Centro de Investigación Esquel de Montaña y Estepa Patagónica. Universidad Nacional de la Patagonia "San Juan Bosco". Centro de Investigación Esquel de Montaña y Estepa Patagónica; ArgentinaFil: Pacheco Cordeiro, Danilo. Instituto Nacional Da Mata Atlantica; BrasilFil: Silva Nogueira, David. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Almeida Marques, Dayse Willkenia. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Nunes Barbosa, Diego. Universidade Federal do Paraná; BrasilFil: Mello Mendes, Diego Matheus. Instituto de Desenvolvimento Sustentável Mamirauá; BrasilFil: Galvão de Pádua, Diego. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Silva Vilela, Diogo. Universidade Estadual Paulista Julio de Mesquita Filho; BrasilFil: Gomes Viegas, Eduarda Fernanda. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; BrasilFil: Carneiro dos Santos, Eduardo. Universidade Federal do Paraná; BrasilFil: Rodrigues Fernandes, Daniell Rodrigo. Ministério da Ciência, Tecnologia, Inovações. Instituto Nacional de Pesquisas da Amazônia; Brasi

Genomic Variants and Worldwide Epidemiology of Breast Cancer: A Genome-Wide Association Studies Correlation Analysis

Breast cancer (BCa) is the most common cancer and leading cause of cancer death among women globally. This can be explained by the genetic factor of this disease. This article aims to correlate the epidemiological data, worldwide incidence, and mortality of BCa with the Single-Nucleotide Polymorphisms (SNPs) associated with the susceptibility and severity in different populations. Two hundred and forty genetic variants associated with BCa susceptibility/severity were selected from the literature through Genome-Wide Association Studies (GWAS). The allele frequencies were obtained from the 1000 Genomes Project, and the epidemiological data were obtained from the World Health Organization (WHO). The BCa incidence, mortality rates, and allele frequencies of the variants were evaluated using Pearson’s correlation. Our study demonstrated that 11 SNPs (rs3817578, rs4843437, rs3754934, rs61764370, rs780092, rs2290203, rs10411161, rs6001930, rs16886165, rs8051542 and rs4973768) were significantly correlated with the epidemiological data in different ethnic groups. Seven polymorphisms (rs3817578, rs3754934, rs780092, rs2290203, rs10411161, rs6001930 and rs16886165) were inversely correlated with the incidence rate and four polymorphisms (rs4843437, rs61764370, rs8051542 and rs4973768) were directly correlated with the incidence rate. African and South-East Asian populations have a lower risk of developing BCa when evaluated in terms of genetic factors since they possess variants characterized as protective, as their higher incidence is associated with a lower frequency of BCa cases. The genetic variants investigated here are likely to predispose individuals to BCa. The genetic study described here is promising for implementing personalized strategies to screen for breast cancer in diverse populations

Long term outcomes of 176 patients with X-linked hyper IgM syndrome treated with or without hematopoietic cell transplantation

X-linked hyper IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared to normal individuals. Hematopoietic cell transplant (HCT) has been considered a curative therapy, but the procedure has inherent complications, and may not be available for all patients.publisher: Elsevier articletitle: Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation journaltitle: Journal of Allergy and Clinical Immunology articlelink: http://dx.doi.org/10.1016/j.jaci.2016.07.039 content_type: article copyright: © 2016 American Academy of Allergy, Asthma & Immunologystatus: publishe

Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation

Background X-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients. Objectives We sought to collect data on the clinical presentation, treatment, and follow-up of a large sample of patients with XHIGM to (1) compare long-term overall survival and general well-being of patients treated with or without HCT along with clinical factors associated with mortality and (2) summarize clinical practice and risk factors in the subgroup of patients treated with HCT. Methods Physicians caring for patients with primary immunodeficiency diseases were identified through the Jeffrey Modell Foundation, United States Immunodeficiency Network, Latin American Society for Immunodeficiency, and Primary Immune Deficiency Treatment Consortium. Data were collected with a Research Electronic Data Capture Web application. Survival from time of diagnosis or transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and modeled by using proportional hazards regression. Results Twenty-eight clinical sites provided data on 189 patients given a diagnosis of XHIGM between 1964 and 2013; 176 had valid follow-up and vital status information. Sixty-seven (38%) patients received HCT. The average follow-up time was 8.5 ± 7.2 years (range, 0.1-36.2 years). No difference in overall survival was observed between patients treated with or without HCT (P = .671). However, risk associated with HCT decreased for diagnosis years 1987-1995; the hazard ratio was significantly less than 1 for diagnosis years 1995-1999. Liver disease was a significant predictor of overall survival (hazard ratio, 4.9; 95% confidence limits, 2.2-10.8; P < .001). Among survivors, those treated with HCT had higher median Karnofsky/Lansky scores than those treated without HCT (P < .001). Among patients receiving HCT, 27 (40%) had graft-versus-host disease, and most deaths occurred within 1 year of transplantation. Conclusion No difference in survival was observed between patients treated with or without HCT across all diagnosis years (1964-2013). However, survivors treated with HCT experienced somewhat greater well-being, and hazards associated with HCT decreased, reaching levels of significantly less risk in the late 1990s. Among patients treated with HCT, treatment at an early age is associated with improved survival. Optimism remains guarded as additional evidence accumulates

Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.

BackgroundX-linked hyper-IgM syndrome (XHIGM) is a primary immunodeficiency with high morbidity and mortality compared with those seen in healthy subjects. Hematopoietic cell transplantation (HCT) has been considered a curative therapy, but the procedure has inherent complications and might not be available for all patients.ObjectivesWe sought to collect data on the clinical presentation, treatment, and follow-up of a large sample of patients with XHIGM to (1) compare long-term overall survival and general well-being of patients treated with or without HCT along with clinical factors associated with mortality and (2) summarize clinical practice and risk factors in the subgroup of patients treated with HCT.MethodsPhysicians caring for patients with primary immunodeficiency diseases were identified through the Jeffrey Modell Foundation, United States Immunodeficiency Network, Latin American Society for Immunodeficiency, and Primary Immune Deficiency Treatment Consortium. Data were collected with a Research Electronic Data Capture Web application. Survival from time of diagnosis or transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and modeled by using proportional hazards regression.ResultsTwenty-eight clinical sites provided data on 189 patients given a diagnosis of XHIGM between 1964 and 2013; 176 had valid follow-up and vital status information. Sixty-seven (38%) patients received HCT. The average follow-up time was 8.5&nbsp;±&nbsp;7.2&nbsp;years (range, 0.1-36.2&nbsp;years). No difference in overall survival was observed between patients treated with or without HCT (P&nbsp;=&nbsp;.671). However, risk associated with HCT decreased for diagnosis years 1987-1995; the hazard ratio was significantly less than 1 for diagnosis years 1995-1999. Liver disease was a significant predictor of overall survival (hazard ratio, 4.9; 95% confidence limits, 2.2-10.8; P&nbsp;&lt;&nbsp;.001). Among survivors, those treated with HCT had higher median Karnofsky/Lansky scores than those treated without HCT (P&nbsp;&lt;&nbsp;.001). Among patients receiving HCT, 27 (40%) had graft-versus-host disease, and most deaths occurred within 1&nbsp;year of transplantation.ConclusionNo difference in survival was observed between patients treated with or without HCT across all diagnosis years (1964-2013). However, survivors treated with HCT experienced somewhat greater well-being, and hazards associated with HCT decreased, reaching levels of significantly less risk in the late 1990s. Among patients treated with HCT, treatment at an early age is associated with improved survival. Optimism remains guarded as additional evidence accumulates